AbbVie Inc. (ABBV)
Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with Irritable Bowel Syndrome with Diarrhea (IBS-D)
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D). The Phase II trial did not meet its primary or key secondary endpoints. Based on these findings, Ironwood and AbbVie plan to discontinue the development of MD-7246. Results from a previously announced MD-7246 Phase II tri
Corporate Funders Support COVID-19 Relief (Update – 05/26/2020)
U.S.-based corporate funders announcing commitments in support of COVID-19 relief and response efforts include AbbVie, Eastman, PepsiCo, Perdue Farms, and USAA….
Today's Pickup: Gartner releases annual Supply Chain Top 25
Good day, Gartner, Inc. released the results from its annual Supply Chain Top 25 , identifying supply chain leaders and highlighting their best practices. Cisco Systems scored the top spot in the ranking, followed by Colgate-Palmolive, Johnson & Johnson, Schneider Electric, and Nestlé. Six new companies joined this year's list – Lenovo, AbbVie, British American Tobacco, Reckitt Benckiser, Biogen, and Kimberly-Clark. Three key trends stand out this year for the companies that made the list, Gartner said in a press release. They use a "language of purpose," recognize that problem solving requires partnership with others in the community and were early and frequent adopters of digital technologies. Did you know? Gross margins for truckload activity managed by 3PLs declined 210 basis points in the first quarter of 2020 compared to a year ago. Intermodal … Full story available on
Zacks Value Trader Highlights: AbbVie, B&G Foods, H&R Block, Microsoft and Apple
Zacks Value Trader Highlights: AbbVie, B&G Foods, H&R Block, Microsoft and Apple
Is AbbVie (ABBV) Stock a Solid Choice Right Now?
AbbVie (ABBV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Bill Maris the founder of Google biotech spinoff Calico says he's 'disappointed' with the progress it's made in anti-aging research since he left: 'It's not how I envisioned it at all' (GOOG)
Bill Maris, who founded Google Ventures and left to build his own investment fund called Section 32, has just brought aboard several ex-Googlers to his new company. Among those is Claire Stapleton, a previous YouTube executive who led an employee walkout at Google in 2018 to protest the company's handling of sexual misconduct allegations. But Maris also founded Calico, the secretive life sciences division that still sits under Alphabet. He said he's "disappointed" with the lack of progress Calico has shown since his departure. Click here to get BI Prime's weekly 'Trending' tech newsletter in your email inbox. Bill Maris, the founder of Google Ventures and creator of Alphabet life sciences division Calico, parted ways with Google in 2016 to form his own investment fund, Section 32. According to Maris, Section 32 is currently investing in a little over 40 companies, and has just added a handful of new members to its ranks – most of which also hail from the Google mothership. They include Claire Stapleton, a previous YouTube executive who led an employee walkout in 2018 over Google's handling of sexual misconduct allegations against former exec Andy Rubin.
AbbVie : Synlogic Shares Fall as AbbVie Collaboration Ends | MarketScreener
By Colin Kellaher Shares of Synlogic Inc. fell more than 25% in premarket trading Thursday after the biopharmaceutical company said its collaboration with AbbVie Inc. had ended. Synlogic… | May 21, 2020
Synlogic Announces Termination of AbbVie Collaboration Agreement
CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the termination of its collaboration with AbbVie, a global, research-based…
Bull of the Day: AbbVie (ABBV)
Bull of the Day: AbbVie (ABBV)
Gilead (GILD): why this stock is undervalued
Gilead stock looks slightly undervalued at this point because the market is undervaluing Gilead’s HIV and oncology portfolios. What is the potential for this stock?
AbbVie (ABBV): Will The Stock Recover?
ABBV diverted the Rova-T program today—and that led to its stock price fall by 13%. When will the stock bounce back?
Follow Us